close

Register today to unlock Valuecruncher and get unlimited access

  • Get unlimited access to all compartors and data
  • Save and share valuations as well as comment on others
  • Alter and save your favourite comparator companies

Already registered? Please login now

Comparison Analysis  

What's this?
Dollar33Point71
Implied share price

Sell Overvalued by 56.9%

5% margin of safety What's this?

EV / Revenue
Use Average
ABII
Abraxis Bioscience, Inc.
AZN
AstraZeneca plc (ADR)
Change
AMGN
Amgen, Inc.
Change
GILD
Gilead Sciences, Inc.
Change
SNY
Sanofi SA (ADR)
Change
3.23 8.25 2.02 5.94 3.45 1.64
All amounts in millions
from last financial year
         
Implied Share Price $33.71 $56.67 $93.51 $74.31 $81.87
Market Cap 3,166 173,797 128,695 105,269 100,826
Net Debt -203 8,200 47 7,450 7,330
Enterprise Value (EV) 2,963 49,995 128,742 112,719 57,252
Revenue 359 24,708 21,662 32,639 34,861
Balance Sheet          
Total Assets 1,068 60,124 71,449 51,716 102,321
Total Liabilities 225 41,634 43,366 33,182 44,272
Shareholders Equity 842 18,490 28,083 18,534 58,049.0

Where are the EBIT and EBITDA figures?

Certain companies and those in specific industries (for example insurance) do not report financial results at the EBIT or EBITDA line. For these companies where Valuecruncher does not have EBIT or EBITDA numbers we exclude the valuation metrics driven by these figures. Valuecruncher makes our other valuation metrics available for these companies.

To learn more about comparison analysis, please read our guide to comparison analysis

Comments

No comments yet. Login to comment.